Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer — Stella

Home/Small Cell Lung Cancer/ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

View on ClinicalTrials.gov

Recruiting

Back to Small Cell Lung Cancer trials

ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of Southern California, Los Angles, California

Key details

Phase

Early testing

Sponsor

SciTech Development, Inc.

Enrollment target

~44 participants

Started

December 2025

Primary completion

May 2027

Age range

18 Years and older

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.